| Budget Amount *help |
¥1,900,000 (Direct Cost: ¥1,900,000)
Fiscal Year 1993: ¥400,000 (Direct Cost: ¥400,000)
Fiscal Year 1992: ¥1,500,000 (Direct Cost: ¥1,500,000)
|
|---|
| Research Abstract |
1. sialosyl-Lewis^x
We examined expression of sialosyl-Lewis^x in blood cells. Sialosyl-Lewis^x was expressed in granulocytes, monocytes and granulocyte-monocyte precursors but not in normal CD34-positive cells. In lymphoid cells, sialosyl-Lewis^x was transiently expressed in CD10-positive cells of B-cell precursors. Since sialosyl-Lewis^x was highly expressed in CD34-positive leukemic cells, the leukemic cells were suggested to over-express CD34. Accordingly, for autologous bone marrow transplantation, anti-sialosyl-Lewis^x antibody was suggested to be useful for eleminating reidual leukemic cells from bone marrow cells in leukemia patients in complete remission.
2. sialosyl-Tn
We examined expession of sialosyl-Tn which was one of the criptic antigens of glycophorin A.Sialosyl-Tn was expressed in CFU-E to erythroblasts but not in normal CD34-positive cells and BFU-E.In leukemic cells, sialosyl-Tn was highly expressed in erythroleukemia cells (M6). In lymphoid cells, sialosyl-Tn was expressed in mature B-cells and a subset of T-cells. Since sialosyl-Tn was not expressed in CD10-positive cells of B-cell precursors and acute lymphoblastic leukemia cells, the antigen was suggested to be only expressed in mature lymphocytes. Although the nature of sialosyl-Tn was unclear, expression pattern of sialosyl-Tn was similar to that of CD22.
|
